LYSANDO-AG
2.8.2021 08:02:09 CEST | Business Wire | Press release
South Korean KOSDAQ listed AMICOGEN Inc. will become the latest shareholder in Lysando AG. The transaction includes an acquisition of shares, a cash contribution to Lysando and a share package to Lysando into AMICOGEN.
The deal means an 8% participation of AMICOGEN into Lysando and 2.69% in shares for Lysando into AMICOGEN. The transactions were negotiated with a 300 Mio. Euro evaluation of Lysando.
Other shareholders of Lysando continue to be majority owner and Chairman of the Board Markus Graf Matuschka von Greiffenclau, Bangkok based SCG, and Lysando’s employees.
The companies have already a productive partnership in place, based on Lysando´s leading platform Artilysin® . It is a globally patented, sustainable and highly effective technology, fighting resistance of microbes, as an alternative to antibiotics and other antimicrobial treatments.
„I am very happy and proud to welcome AMICOGEN as a new shareholder of Lysando. AMICOGEN being such a strong and successfully operating CDMO, Asian markets, in particular China and South Korea, can now be approached faster and with the highest level of sufficiency. Our microbiome-friendly Artilysin® -platform has incredible potential for the benefit of humanity, pets, farmed animals and the environment which can be implemented even better now“, says Lysando´s chairman Markus Graf Matuschka von Greiffenclau.
„Global spreading resistance and our increasing knowledge about the importance of a balanced microbiome require innovation and a new way of thinking. We had been impressed with the potential of Artilysin® from the very beginning. I am looking very much forward pushing our partnership to the next level, intensifying our company´s interfaces and therefore merge know-how to even further drive the success and growth of the Artilysin® -platform.”, says Yong Chul Shin, CEO of AMICOGEN.
Amicogen Inc.
Amicogen Inc., 092040:KOSDAQ develops, produces and markets specialty enzymes and functional food ingredients. The company offers special biocatalysts, enzyme-based new functional materials, health foods, and consumer products.
Lysando AG
Lysando AG is market-leader for antimicrobial proteins, so-called Artilysin®
s.
Artilysin®
s are a new class of molecules showing a high resistance stability and are microbiome- and environmentally-friendly. Artilysin®
s can be employed in all fields, bacteria present a problem like Medical Devices, Human Pharmaceutics, Animal Health and Consumer Care.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210801005009/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Calvin Klein Fragrances announces ROSALÍA as the face of new euphoria elixirs19.2.2026 14:30:00 CET | Press release
Campaign fronted by the global superstar and brand ambassador explores the distinct universes of the three new parfums Calvin Klein, Inc., part of PVH Corp. [NYSE: PVH], and Calvin Klein Fragrances, a division of Coty Inc. [NYSE: COTY], today unveil GRAMMY® Award-winning singer-songwriter ROSALÍA as the face of euphoria elixirs, a new collection of three distinct parfum intense creations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219549836/en/ Calvin Klein Fragrances announces ROSALÍA as the face of new euphoria elixirs. A daring new chapter of the iconic euphoria franchise, euphoria elixirs are a sensorial exploration of confidence, pleasure and sensuality. Embodied by global icon and Calvin Klein ambassador ROSALÍA, the campaign fuses movement and vivid color into a captivating exploration of freedom without limits. Known for her genre-defying sound and commanding visual artistry, ROSALÍA channels the fragrances’ m
ExaGrid Achieves Customer Milestone19.2.2026 14:00:00 CET | Press release
5,000+ organizations worldwide are actively using ExaGrid Tiered Backup Storage ExaGrid®, the leader in Tiered Backup Storage, today announced that over 5,000 customers are actively using its backup storage behind leading backup applications such as Veeam, Commvault, NetBackup, Rubrik, Arcserve, Acronis, SQL Dumps, Oracle RMAN Direct, HYCU, and many other backup applications and utilities. ExaGrid has achieved many milestones, including: +81 NPS score The highest in the backup storage industry 300+ published backup storage customer success stories on its website More than all competitors combined 200+ Gartner Peer Insights reviews With a high rating of 4.8/5 stars 24 Industry Awards in the last 3 years More than any other backup storage provider Over 20 consecutive quarters with positive: Free Cash Flow, P&L and EBITDA “ExaGrid realized that using standard primary storage behind a backup application is not a strong solution, and with any level of retention it’s very expensive as well a
DCO Launches Global “Ctrl+Alt+Delete” Campaign to Combat Online Misinformation and Enhance Trust in Digital Economy19.2.2026 13:25:00 CET | Press release
The “Stop Online Misinformation” campaign marks the culmination of sustained global collaboration to strengthen trust in the safe and all-inclusive digital economy The Digital Cooperation Organization (DCO) has announced the launch of the “Stop Online Misinformation: Ctrl+Alt+Delete,” global campaign to counter online misinformation and strengthen trust in the digital economy, calling for coordinated action by governments, media, the private sector, and digital platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218141056/en/ DCO Launches Global “Ctrl+Alt+Delete” Campaign to Combat Online Misinformation and Enhance Trust in Digital Economy - (Photo: AETOSWire) The campaign represents the culmination of a year of sustained multilateral and multistakeholder engagement led by DCO to address misinformation as a growing economic, societal, and trust-related challenge. Underpinned by DCO’s Online Content Integrity initiat
Amazfit Announces the T-Rex Ultra 2: a Titanium GPS Watch Engineered for the Extreme19.2.2026 13:00:00 CET | Press release
With preloaded global maps, intelligent route tools, and weeks-long battery life, the T-Rex Ultra 2 is made for those who seek boundaries only to push beyond Amazfit, a leading global smart wearable brand owned by Zepp Health, today announced the T-Rex Ultra 2, the latest and most advanced member of its rugged T-Rex lineup. As part of the T-Rex family, the T-Rex Ultra 2 is built for uncertainty—designed to remain reliable in conditions where plans, environments, and outcomes are never fully defined. Purpose-built for extreme environments, the T-Rex Ultra 2 combines premium materials, enhanced navigation capabilities, and extended battery life to support athletes and explorers tackling long, complex routes where preparation and reliability matter most. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219679075/en/ Amazfit Announces the T-Rex Ultra 2: a Titanium GPS Watch Engineered for the Extreme “With the T-Rex Ultra 2, we
YolTech Therapeutics Announces Positive Interim Data on YOLT-202 for the Treatment of Alpha-1 Antitrypsin Deficiency19.2.2026 12:00:00 CET | Press release
Single dose of YOLT-202 led to rapid, robust and dose-dependent increases in AAT levels to normal rangeSingle dose of YOLT-202 was well tolerated with a favorable safety profile YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene editing therapies, today announced positive interim data from an investigator-initiated trial (IIT) of YOLT-202, the Company’s investigational in vivo base editing therapy, for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) that demonstrated positive safety and tolerability as well as meaningful increases in AAT levels in evaluated patients treated with the 35 mg and 45 mg dose levels. “These interim findings mark an exciting and important milestone for YolTech and for patients living with severe AATD. The rapid, robust, and dose‑dependent increases in functional AAT levels observed in this study—particularly among individuals with the PiZZ genotype—underscore the transformative potential of in vivo base editing as
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom